CLINICAL_TRIALS
trial_result
· 2019-04-04
Clinical Trial Update: Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC [Phase 3]
Summary
Phase 3 trial evaluating the combination of Apatinib with EGFR-TKI in advanced EGFR-TKI resistant non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shenzhen People's Hospital | Conditions: NSCLC, Apatinib | Phase 3 | Status: UNKNOWN